NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 07, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors
February 19, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors ...
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
February 05, 2024 07:00 ET
|
NodThera
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
NodThera announces first patients dosed in a Phase Ib/IIa cardiovascular risk trial of NLRP3 inflammasome inhibitor NT-0796
October 16, 2023 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) Aberrant NLRP3 activation is recognised as a critical driver of cardiometabolic diseaseA Phase Ib/IIa trial of lead candidate NT-0796 will assess...
NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor
July 11, 2023 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor NT-0796 demonstrates...
NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors
June 20, 2023 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors Oral, small molecule, clinical candidates NT-0249...
NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening of its laboratory in Seattle
October 23, 2018 07:00 ET
|
NodThera
NodThera Ltd(“NodThera” or the “Company”) NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening...
NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening of its laboratory in Seattle
October 23, 2018 02:00 ET
|
NodThera
NodThera Ltd(“NodThera” or the “Company”) NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening...
NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer
September 24, 2018 07:00 ET
|
NodThera
NodThera(“NodThera” or the “Company”) NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer Dr Keeney joins NodThera with over 20 years of...
NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer
September 24, 2018 02:00 ET
|
NodThera
NodThera(“NodThera” or the “Company”) NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer Dr Keeney joins NodThera with over 20 years of...